Tumores odontogênicos: estudo clínico-patológico de 238 casos

Os tumores odontogênicos são neoplasias que se desenvolvem exclusivamente nos ossos gnáticos, originando-se dos tecidos odontogênicos por proliferação de tecido epitelial, mesenquimal ou ambos. OBJETIVO: Avaliar a incidência de tumores odontogênicos em determinada instituição e comparar com outros estudos da literatura mundial. FORMA DE ESTUDO: Estudo de coorte transversal. MATERIAL E MÉTODO: O material do estudo foi levantado a partir dos registros de pacientes com tumores odontogênicos, no período de janeiro de 1992 a março de 2007 (15 anos). Foram incluídos os casos de pacientes que se enquadravam na Classificação Histológica da Organização Mundial de Saúde (OMS) de 2005. Foram analisados os indicadores gênero, faixa etária, localização anatômica, tipo histológico e presença de sintomatologia. RESULTADOS: Os tumores odontogênicos constituíram 4,76% dentre todas as lesões biopsiadas dentro do período estudado. A idade média dos pacientes foi de 30,7 anos, 57% dos pacientes eram do gênero masculino. O tumor odontogênico ceratocístico foi o tipo histológico mais prevalente (30%), seguido do ameloblastoma (23,7%). Quanto à presença de sintomatologia, 75,7% dos casos apresentaram-se assintomáticos. CONCLUSÃO: Os tumores odontogênicos parecem ter discreta predileção pelo gênero feminino, segunda e terceira décadas de vida, sendo mais freqüentes na mandíbula e, na maioria dos casos apresentam-se assintomáticos.

Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients

Certain host single nucleotide polymorphisms (SNPs) affect the likelihood of a sustained virological response (SVR) to treatment in subjects infected with hepatitis C virus (HCV). SNPs in the promoters of interleukin (IL)-10 (-1082 A/G, rs1800896), myxovirus resistance protein 1 (-123 C/A, rs17000900 and -88 G/T, rs2071430) and tumour necrosis factor (TNF) (-308 G/A, rs1800629 and -238 G/A, rs361525) genes and the outcome of PEGylated α-interferon plus ribavirin therapy were investigated. This analysis was performed in 114 Brazilian, HCV genotype 1-infected patients who had a SVR and in 85 non-responders and 64 relapsers. A significantly increased risk of having a null virological response was observed in patients carrying at least one A allele at positions -308 [odds ratios (OR) = 2.58, 95% confidence intervals (CI) = 1.44-4.63, p = 0.001] or -238 (OR = 7.33, 95% CI = 3.59-14.93, p < 0.001) in the TNF promoter. The risk of relapsing was also elevated (-308: OR = 2.87, 95% CI = 1.51-5.44, p = 0.001; -238: OR = 4.20, 95% CI = 1.93-9.10, p < 0.001). Multiple logistic regression of TNF diplotypes showed that patients with at least two copies of the A allele had an even higher risk of having a null virological response (OR = 16.43, 95% CI = 5.70-47.34, p < 0.001) or relapsing (OR = 6.71, 95% CI = 2.18-20.66, p = 0.001). No statistically significant association was found between the other SNPs under study and anti-HCV therapy response.

Use of steel slag to neutralize acid mine drainage (AMD) in sulfidic material from a uranium mine

Acid Mine Drainage (AMD) is one of the main environmental impacts caused by mining. Thus, innovative mitigation strategies should be exploited, to neutralize acidity and prevent mobilization of trace elements in AMD. The use of industrial byproducts has been considered an economically and environmentally effective alternative to remediate acid mine drainage. Therefore, the objective of this study was to evaluate the use of steel slag to mitigate acid mine drainage in a sulfidic material from a uranium mine, as an alternative to the use of limestone. Thus, increasing doses of two neutralizing agents were applied to a sulfidic material from the uranium mine Osamu Utsumi in Caldas, Minas Gerais State. A steel slag from the company ArcelorMittal Tubarão and a commercial limestone were used as neutralizing agents. The experiment was conducted in leaching columns, arranged in a completely randomized, [(2 x 3) + 1] factorial design, consisting of two neutralizing agents, three doses and one control, in three replications, totaling 21 experimental units. Electrical conductivity (EC), pH and the concentrations of Al, As, Ca, Cd, Cu, Fe, Mn, Ni, S, Se, and Zn were evaluated in the leached solutions. The trace element concentration was evaluated by ICP-OES. Furthermore, the CO2 emission was measured at the top of the leaching columns by capturing in NaOH solution and titration with HCl, in the presence of BaCl2. An increase in the pH of the leachate was observed for both neutralizing agents, with slightly higher values for steel slag. The EC was lower at the higher lime dose at an early stage of the experiment, and CO2 emission was greater with the use of limestone compared to steel slag. A decrease in trace element mobilization in the presence of both neutralizing agents was also observed. Therefore, the results showed that the use of steel slag is a suitable alternative to mitigate AMD, with the advantage of reducing CO2 emissions to the atmosphere compared to limestone.

Quantification of the uranium concentration in human urine by inductively coupled plasma-sector field mass spectrometry (ICP-SFMS)

In this study, the validation of a method for analyzing the uranium (U) concentration in human urine samples by inductively coupled plasma-sector field mass spectrometry (ICP-SFMS) was conducted. PROCORAD (the Association for the Promotion of Quality Control in Radiotoxicological Analysis) provided two urine samples spiked with unknown contents of U (Sample A = 33.6 ± 1.0 µg/L and Sample B = 3.3 ± 0.1 µg/L) and one unspiked sample as a blank. The analyses were directly performed on the diluted urine samples (dilution factor = 1:20) in 5% v/v HNO3. The results obtained by ICP-SFMS corresponded well with the reference values, and the limits of detection were 235U = 0.049 × 10-3 µg/L and 238U = 7.37 × 10-3 µg/L. The ICP-SFMS technique has been shown to be successful in the analysis of the U concentration in human urine samples and for the quantification of isotopic ratios.